Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-305B83 + FOLFIRI
- Development stage
- Unknown
- Lead developer
- OncXerna Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
OMP-305B83 + FOLFIRI is a combination therapy consisting of **OMP-305B83** (also known as navicixizumab), a humanized bispecific monoclonal antibody targeting both Delta-like ligand 4 (DLL4, a Notch pathway ligand) and vascular endothelial growth factor (VEGF), plus **FOLFIRI** (a chemotherapy regimen of folinic acid, fluorouracil, and irinotecan). OMP-305B83 is designed to block tumor angiogenesis and disrupt cancer stem cell maintenance through dual inhibition of DLL4 and VEGF signaling. The combination is being investigated for use in patients with metastatic colorectal cancer who have progressed on first-line therapies[1][2][3].
- Brand names
- navicixizumab
- Other names
- anti-DLL4/VEGF bispecific antibody + FOLFIRI
02
Targets
Beyond the preview
Go deeper on OMP-305B83 + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-305B83 + FOLFIRI.